Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples